Individual research recommendation details

Recommendation ID

NG191/11

Question

What are the possible outcomes for people who are critically ill and have COVID-19-associated pulmonary aspergillosis (CAPA)?

Any explanatory notes
(if applicable)

Population: adults, young people and children who are critically ill and have, or have had, COVID-19 as part of their acute illness, and who have CAPA. Subgroups of particular interest: young people and children, pregnant women, ethnicity, immunosuppression and subgroups who have higher rates of COVID-19.

Outcomes:
• presence of fungal serum biomarkers (for example galactomannan and beta-D-glucan)
• measures of inflammation (for example C-reactive protein)
• need for respiratory support (for example, invasive mechanical ventilation or extracorporeal membrane oxygenation [ECMO])
• hospitalisation metrics (for example, mortality, length of hospital stay, admission to and length of stay in intensive care)
• long-term morbidity outcomes, functional measures and patient outcomes
• results may be stratified (for example, disease severity, use of ECMO)

Source guidance details

Comes from guidance

COVID-19 rapid guideline: managing COVID-19

Number

NG191

Date issued

March 2021

Other details